| Followers | 2421 |
| Posts | 92347 |
| Boards Moderated | 1 |
| Alias Born | 09/12/2003 |
Thursday, February 27, 2020 1:25:20 AM
$TNXP Founded in 1941, Southern Research (SR) is an independent, 501(c)(3) nonprofit, scientific research organization with more than 400 scientists and engineers working across four divisions: Drug Discovery, Drug Development, Engineering, and Energy & Environment. SR supports the pharmaceutical, biotechnology, defense, aerospace, environmental, and energy industries as we work on behalf of the National Cancer Institute, National Institutes of Health, the U.S. Department of Defense, the U.S. Department of Energy, NASA, major aerospace firms, utility companies, and other private and government organizations. We pursue entrepreneurial and collaborative initiatives to develop and maintain a pipeline of intellectual property and innovative technologies that positively impact real-world problems. SR is headquartered in Birmingham with additional laboratories and offices in Wilsonville, Alabama; Frederick, Maryland; Cartersville, Georgia; and Houston, Texas./b]
https://www.linkedin.com/company/southernresearch
https://southernresearch.org/about/
https://en.wikipedia.org/wiki/Southern_Research
We're proud to announce a new collaboration with Tonix Pharmaceuticals to develop a potential vaccine for COVID-19.
https://www.linkedin.com/company/southernresearch
https://southernresearch.org/about/
https://en.wikipedia.org/wiki/Southern_Research
Recent TNXP News
- Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting • GlobeNewswire Inc. • 05/28/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/27/2026 11:05:55 AM
- Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology • GlobeNewswire Inc. • 05/27/2026 11:00:00 AM
- Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting • GlobeNewswire Inc. • 05/26/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 01:25:40 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 05/15/2026 12:06:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:48:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:47:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:46:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 09:45:40 PM
- Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026 • GlobeNewswire Inc. • 05/14/2026 11:00:00 AM
- Tonix Pharmaceuticals to Participate in Two Investor Conferences in May • GlobeNewswire Inc. • 05/12/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 09:17:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/11/2026 09:15:25 PM
- Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights • GlobeNewswire Inc. • 05/11/2026 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 09:20:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:05:40 AM
- Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/01/2026 08:57:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:28 AM
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at J • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/23/2026 11:11:37 AM
- Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026 • GlobeNewswire Inc. • 04/23/2026 11:00:00 AM
- Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development • GlobeNewswire Inc. • 04/15/2026 11:00:00 AM

